Events
At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest ac...
November 20, 2025 | News
A major step forward in regional collaboration for cancer care was announced today with the launch of Project ACTIVE 2.0 (Advancing Cervical Cancer Tr...
November 14, 2025 | News
LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Materi...
November 14, 2025 | News
SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pac...
November 12, 2025 | News
Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control obser...
November 11, 2025 | News
Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-...
November 10, 2025 | News
The Centre for Global Allied Health and Centre for Global Pharmacy will advance global health collaboration and capacity building, with a focus on streng...
November 06, 2025 | Report
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration w...
October 30, 2025 | News
Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across K...
October 28, 2025 | News
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor recep...
October 20, 2025 | News
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study de...
October 20, 2025 | News
Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization ACROBiosystems, tog...
October 13, 2025 | Report
Most Read
Bio Jobs
News
Editor Picks